Search academic texts

Information × Registration Number 0217U000995, 0114U002150 , R & D reports Title Study the results of different kind methods of the treatment autoimmune ophthalmopathy in the Grave's deseases popup.stage_title Head Oliynyk Valeriy Anatoliyovich, Registration Date 28-03-2017 Organization State institution "V.P. Komisarenko Institute of Endocrynology and Metabolism of the National Academy of Medical Science of Ukraine" popup.description2 Research object: remote results of treatment of oculopathy for patients by a diffuse toxic goitre, risk of her development factors.Aim: on the basis of analysis of flow of disease, efficiency of surgical methods of treatment of the diffuse toxic goitre complicated by an oculopathy, to work out the optimal charts of her prophylaxis and treatment. Methods: questionnaire, clinical, ophthalmology inspection, ULTRASONIC of orbits, hormonal, biochemical, 24-hours monitoring of cardiac rhythm. Results: The patients by the diffuse toxic goitre complicated by an oculopathy was observed. Before treatment for all patients the decline of level of Thyrotropinum of blood and increase of levels of free thyroxine and triiodo-thyronine are reduce (Р<0,05). that testified to decompensation of thyrotoxicosis. For all patients a level of antibodies to the receptor of Thyrotropinum was elevated (Р<0,05). From data of ULTRASONIC of orbits the biggest of retrobulbar cellulose is educed, edema of chorioretinal complex and miopathy of muscles of orbit. The decline of self-appraisal and quality of life is marked. The level of antibodies to the receptor of Thyrotropinum for patients with an oculopathy and diffuse toxic goiter considerably exceeds the same index for patients without an oculopathy and decriase in the process of thyreostatic therapy. After surgical treatment in the volume of thyroidectomy for patients regress of displays of oculopathy is marked, decline of levels of antibodies to the receptor of Thyrotropinum already in 6 months after an operation. Efficiency and safety of the use of chart pulstherapy Methylprednisolonum are well-proven in a dose 750 mgs/24-hours (2250 summary dose), that conducts to регресу displays of oculopathy, to the decline of levels of antibodies to the receptor of Thyrotropinum and upgrading of life of patients. The reduce of vitamine D and selenium levels (Р<0,05). Degree of introduction: the articles, lectures, patents. Application domain: endocrinology, ophthalmology, family medicine. Product Description popup.authors Булдигіна Юлія Валеріївна Олійник Валерій Анатолійович Терехова Галина Николаевна popup.nrat_date 2020-04-02 Close